Toronto Dominion Bank Sells 26,368 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Toronto Dominion Bank decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 107,834 shares of the pharmaceutical company’s stock after selling 26,368 shares during the quarter. Toronto Dominion Bank’s holdings in Vertex Pharmaceuticals were worth $43,424,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in VRTX. Truvestments Capital LLC grew its holdings in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after buying an additional 23 shares in the last quarter. Simon Quick Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 1.1% during the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock worth $900,000 after acquiring an additional 24 shares during the last quarter. Spinnaker Trust raised its holdings in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company’s stock valued at $497,000 after purchasing an additional 25 shares during the last quarter. Strategic Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 0.6% during the fourth quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company’s stock valued at $1,807,000 after purchasing an additional 25 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its position in shares of Vertex Pharmaceuticals by 0.7% during the fourth quarter. Moors & Cabot Inc. now owns 3,603 shares of the pharmaceutical company’s stock valued at $1,451,000 after purchasing an additional 25 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on VRTX shares. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. BMO Capital Markets set a $545.00 price target on Vertex Pharmaceuticals in a report on Friday, January 31st. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and boosted their price objective for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. Piper Sandler decreased their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Finally, Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 6th. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $515.04.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the sale, the executive vice president now owns 58,539 shares of the company’s stock, valued at approximately $27,825,928.26. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at $13,256,000. This represents a 10.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,005 shares of company stock valued at $1,978,465 over the last three months. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $438.65 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The business has a fifty day moving average price of $482.97 and a 200-day moving average price of $464.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market capitalization of $112.64 billion, a P/E ratio of -199.39, a PEG ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the previous year, the business earned $4.76 earnings per share. Vertex Pharmaceuticals’s revenue was up 2.6% on a year-over-year basis. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.